Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Tech Stock Options -- Ignore unavailable to you. Want to Upgrade?

To: wmwmw who wrote (42175)	5/4/1998 10:01:00 PM
From: jjs_ynot	Respond to of 58727

A reply I got from someone on ENMD thread Dave_s: BMY owns the rights to endostatin the other part of the two protein mix. IMHO neither endostatin nor angiostatin will ever be used as drugs. Screening and mutagenesis will be used to find smaller, more stable, more bioavailable proteins and/or small molecules which do the same biochemistry will be found. Also, since both proteins are naturally occuring substances some fiddling is needed to have strong patent protection. However, this is a big step forward. From what I have been able to gather: - BMY owns 1/2 of the formula outright - BMY has some equity stake in ENMD and the other half of the formula since they are footing a part of the bill somehow (maybe their technology to the table for nothing) - BMY appears to have ultimate production rights to the protein combination In any case, the current formula requires significant refinement and at least 5 years (from what I can tell) of clinical trials before coming to market and BMY appears to own a big piece of any profit. ENMD doesn't look like a great investment IMO.